Form 4: Castle Biosciences Director Daniel Bradbury Sells Shares Under 10b5-1 Plan

Director Daniel Bradbury executed sales of Castle Biosciences (CSTL) common stock on April 4th and 5th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Daniel Bradbury, a director at Castle Biosciences, sold shares of common stock on April 4th and 5th, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on August 22, 2023.
• On April 4th, Bradbury sold 2,901 shares at $21.45 per share directly, and sales were also made indirectly through BioBrit, LLC, The Daniel M. Bradbury Irrevocable Descendants' Trust and The Annette E. Bradbury Irrevocable Descendants' Trust.
• On April 5th, Bradbury sold 3,731 shares at $20.86 per share directly, and sales were also made indirectly through BioBrit, LLC, The Daniel M. Bradbury Irrevocable Descendants' Trust and The Annette E. Bradbury Irrevocable Descendants' Trust.
• The transactions resulted in changes to the number of shares beneficially owned by Bradbury directly and indirectly through various entities.
• The price per share for the transactions on April 4th ranged from $21.18 to $21.84, and on April 5th ranged from $20.76 to $21.23.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The filing simply reports stock sales under a pre-existing 10b5-1 plan, which is a common and legal practice. There's no inherent positive or negative implication.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• While the sales were under a 10b5-1 plan, large insider sales can sometimes negatively impact investor sentiment.

Industry Context

Insider sales are a common occurrence, and the use of a 10b5-1 plan is a standard practice to allow insiders to sell shares without raising concerns about trading on non-public information. Investors often monitor insider activity as an indicator of management's confidence in the company's future prospects.

Comparison to Industry Standards

• It's common for directors and officers of publicly traded companies to have 10b5-1 trading plans in place.
• The volume of shares sold is relatively small compared to the overall outstanding shares of Castle Biosciences, suggesting it's unlikely to have a significant impact on the stock price.
• Comparing the trading activity to other similar-sized biotech companies, this level of insider selling is within a normal range.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates